Cellebrite DI Ltd. - Ordinary Shares (CLBT)

Cellebrite just served up some great news for investors with its latest quarterly report.

Cellebrite (CLBT) Q3 2025 Earnings Call Transcript

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Cellebrite experienced solid growth in Q2 2025, exceeding expectations for sales and earnings. Signs of a rebound are encouraging.

Cellebrite reports mixed Q2 2025 results: revenue slightly misses estimates at $113.3M, while EPS beats at $0.12. New CEO appointed amid leadership changes and strategic acquisitions. Stock dips pre-market.

The Benzinga Stock Whisper Index looks at five stocks seeing increased attention from readers during the week and a look at what could be causing the increased interest.

Earnings news has catalyzed frenzied activity in these stocks, and irrespective of the directional moves, sentiment toward them has remained uniformly upbeat.

In this video lesson, I review the resilient overall market, stocks on my radar for the short and long-term portfolio, and a new EOD swing trade, for Tuesday's session. Happy trading. Aloha.